A Single-blind, Randomised, Placebo-controlled Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Inhaled AZD4604 Following Single Ascending and Multiple Doses in Healthy Japanese and Chinese Participants
Latest Information Update: 16 Jan 2025
At a glance
- Drugs AZD 4604 (Primary)
- Indications Asthma
- Focus Adverse reactions
- Sponsors AstraZeneca
Most Recent Events
- 11 Dec 2024 Status changed from active, no longer recruiting to completed.
- 02 Dec 2024 Status changed from recruiting to active, no longer recruiting.
- 30 Jul 2024 New trial record